Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
作者信息
Dieci M V, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu M C, Delaloge S, Curigliano G, Andre F
机构信息
INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Department of Oncological and Surgical Sciences, University of Padua, Padua Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
Early Drug Development for Innovative Therapies Division, Department of Medicine, Istituto Europeo di Oncologia, Milano.
出版信息
Ann Oncol. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241.
Abstract
摘要
相似文献
1
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
Ann Oncol. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241.
2
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Breast Cancer Res. 2015 Sep 4;17(1):124. doi: 10.1186/s13058-015-0632-x.
3
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Breast Cancer Res Treat. 2018 Feb;168(1):135-145. doi: 10.1007/s10549-017-4575-z. Epub 2017 Nov 22.
4
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Ann Oncol. 2015 Aug;26(8):1698-704. doi: 10.1093/annonc/mdv239. Epub 2015 May 20.
5
Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
Hum Pathol. 2018 Oct;80:47-54. doi: 10.1016/j.humpath.2018.05.024. Epub 2018 Jun 5.
6
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2.
7
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
Ann Oncol. 2018 Jan 1;29(1):162-169. doi: 10.1093/annonc/mdx691.
8
PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Int J Cancer. 2017 Mar 15;140(6):1384-1395. doi: 10.1002/ijc.30552.
9
The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Hum Pathol. 2017 Nov;69:110-117. doi: 10.1016/j.humpath.2017.09.012. Epub 2017 Oct 6.
10
MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
Breast Cancer Res Treat. 2016 Apr;156(3):597-606. doi: 10.1007/s10549-016-3786-z. Epub 2016 Apr 13.
引用本文的文献
1
Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells.
J Immunother Cancer. 2024 Oct 21;12(10):e009510. doi: 10.1136/jitc-2024-009510.
2
Immunogenic chemotherapy: great potential for improving response rates.
Front Oncol. 2023 Dec 6;13:1308681. doi: 10.3389/fonc.2023.1308681. eCollection 2023.
3
Crosstalk between triple negative breast cancer and microenvironment.
Oncotarget. 2023 Mar 31;14:284-293. doi: 10.18632/oncotarget.28397.
4
SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival.
Front Immunol. 2022 Oct 20;13:940635. doi: 10.3389/fimmu.2022.940635. eCollection 2022.
5
Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
Clin Cancer Res. 2022 Oct 14;28(20):4494-4508. doi: 10.1158/1078-0432.CCR-22-0543.
6
The Immune Microenvironment in Gastric Cancer: Prognostic Prediction.
Front Oncol. 2022 Apr 28;12:836389. doi: 10.3389/fonc.2022.836389. eCollection 2022.
7
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions.
Cancers (Basel). 2021 Jul 26;13(15):3739. doi: 10.3390/cancers13153739.
8
VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.
In Vivo. 2020 Sep-Oct;34(5):2641-2646. doi: 10.21873/invivo.12082.
9
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Cancers (Basel). 2020 Aug 24;12(9):2392. doi: 10.3390/cancers12092392.
10
Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
Sci Rep. 2019 Feb 7;9(1):1583. doi: 10.1038/s41598-018-38272-1.
Zotero 插件